Adma Biologics reported $33.74M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Adma Biologics USD 33.74M 16.65M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Novavax USD 22.1M 608K Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Takeda JPY 560.54B 159.39B Mar/2026